Driehaus Capital Management LLC Takes Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Driehaus Capital Management LLC has acquired a new position in Jazz Pharmaceuticals, purchasing 90,550 shares valued at approximately $11.2 million, representing about 0.15% of the company.
• Jazz Pharmaceuticals has received a consensus "Moderate Buy" rating from analysts, with a target price averaging $178.67, as recent reports included upgraded ratings and price adjustments.
• The company's stock recently opened at $127.75 and reported a quarterly EPS of (8.25), missing estimates, but showing a year-over-year revenue increase of 2.1% to $1.05 billion.

Driehaus Capital Management LLC purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 90,550 shares of the specialty pharmaceutical company's stock, valued at approximately $11,242,000. Driehaus Capital Management LLC owned approximately 0.15% of Jazz Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Hurley Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $25,000. Elequin Capital LP grew its stake in Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after acquiring an additional 183 shares during the period. Parallel Advisors LLC increased its holdings in Jazz Pharmaceuticals by 85.6% in the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after acquiring an additional 119 shares in the last quarter. Spire Wealth Management raised its position in Jazz Pharmaceuticals by 137.6% during the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock worth $35,000 after acquiring an additional 161 shares during the period. Finally, Picton Mahoney Asset Management lifted its holdings in Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Down 2.8%

Shares of JAZZ traded down $3.69 during mid-day trading on Thursday, hitting $128.03. 418,215 shares of the company's stock were exchanged, compared to its average volume of 945,055. The stock's 50-day moving average is $115.82 and its 200-day moving average is $117.12. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a market cap of $7.77 billion, a price-to-earnings ratio of -19.00, a P/E/G ratio of 8.04 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the firm earned $5.30 earnings per share. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer directly owned 436,973 shares of the company's stock, valued at $47,031,403.99. This trade represents a 0.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research reports. Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Deutsche Bank Aktiengesellschaft assumed coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price target on the stock. Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Robert W. Baird lowered their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Finally, The Goldman Sachs Group upped their price objective on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a report on Friday, August 29th. Fourteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $178.67.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.